BridgeBio Strengthens Board Retention with Major Equity Package to Director Aguiar

Rhea-AI Filing Summary

BridgeBio Pharma Director Eric Aguiar reported two significant equity transactions on June 20, 2025:

• Restricted Stock Units (RSUs): Acquired 6,589 RSUs at $0 cost, which vest over three years through June 20, 2028
• Stock Options: Received 8,425 options with exercise price of $41.73, vesting over three years and expiring June 19, 2035

Both grants are subject to Aguiar's continued service on BridgeBio's board of directors, with annual vesting of one-third of the awards. The RSUs represent contingent rights to receive common stock shares upon vesting. This compensation package aligns the director's interests with long-term shareholder value through a combination of time-based RSUs and options with a significant exercise price.

Insider Trade Summary

Net Buyer: 6,589 shares

Net Buy 2 txns

Insider AGUIAR ERIC

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,425	$0.00	$0.00
Grant/Award	Common Stock	6,589	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 6,589 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/24/2025 - 07:07 PM Learn about SEC filing dates

FAQ

How many BBIO shares did Eric Aguiar receive in RSUs on June 20, 2025?

Eric Aguiar received 6,589 restricted stock units (RSUs) of BBIO on June 20, 2025. These RSUs will vest over three years, with one-third vesting each year starting from June 20, 2025, until fully vested on June 20, 2028.

What stock options were granted to BBIO director Eric Aguiar in June 2025?

Eric Aguiar was granted stock options to purchase 8,425 shares of BBIO common stock at an exercise price of $41.73 per share on June 20, 2025. The options expire on June 19, 2035, and vest over three years with one-third vesting each year through June 20, 2028.

What is the vesting schedule for BBIO's director Eric Aguiar's June 2025 equity grants?

Both the RSUs and stock options granted to Eric Aguiar on June 20, 2025, follow the same vesting schedule: one-third will vest each year after the grant date, with full vesting occurring on June 20, 2028. This vesting is subject to Aguiar's continued service on BBIO's board of directors.

What is the exercise price of BBIO stock options granted to Eric Aguiar in June 2025?

The stock options granted to Eric Aguiar on June 20, 2025, have an exercise price of $41.73 per share. These options expire on June 19, 2035, ten years after the grant date.

How many BBIO shares does Eric Aguiar beneficially own after the June 2025 grants?

Following the June 20, 2025 grants, Eric Aguiar directly owns 6,589 shares of BBIO common stock (in the form of RSUs) and holds options to purchase an additional 8,425 shares, all subject to vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGUIAR ERIC

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A(1)		6,589	A	$0(2)	6,589	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$41.73	06/20/2025		A		8,425		(3)	06/19/2035	Common Stock	8,425	$0	8,425	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Eric Aguiar, M.D.	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.